Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy

Journal of Immunotherapy

Volumn 36, Issue 9, 2013, Pages 477-489

  Lechner, Melissa G ^a   Karimi, Saman S ^a   Barry Holson, Keegan ^a   Angell, Trevor E ^a   Murphy, Katherine A ^b,c   Church, Connor H ^a   Ohlfest, John R ^b,c   Hu, Peisheng ^a   Epstein, Alan L ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Departments of Pediatrics   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

experimental tumor models; immunogenicity; immunotherapy; MHC class I; suppressor cells

Indexed keywords

ARGINASE 1; B7 ANTIGEN; CD11B ANTIGEN; CD137 LIGAND; CD40 ANTIGEN; CD45 ANTIGEN; CD86 ANTIGEN; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; FLUOROURACIL; GAMMA INTERFERON; GLYCOPROTEIN P 15095; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HILTONOL; HYBRID PROTEIN; INDOLEAMINE 2,3 DIOXYGENASE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 6; L SELECTIN; OX40 LIGAND; PROGRAMMED DEATH 1 LIGAND 1; STAT3 PROTEIN; TOLL LIKE RECEPTOR AGONIST; TRANSFORMING GROWTH FACTOR BETA; TUMOR TARGETED LIVER EXPRESSION CHEMOKINE FUSION PROTEIN; TUMOR VACCINE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; BREAST CANCER; CANCER GRAFT; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; COLON CANCER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EFFECTOR CELL; EXPERIMENTAL NEOPLASM; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE ACTIVATION; GENE EXPRESSION; GLIOBLASTOMA; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CANCER; LOW DRUG DOSE; LUNG CANCER; LYMPHOID TISSUE; MELANOMA B16; MEMORY T LYMPHOCYTE; MOUSE; MURINE SOLID TUMOR MODEL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR MODEL; TUMOR VOLUME; UPREGULATION;

ANIMALS; ANIMALS, NEWBORN; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARGINASE; CANCER VACCINES; CELL LINE, TUMOR; CYTOKINES; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LYMPHOID TISSUE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MYELOID CELLS; NEOPLASMS, EXPERIMENTAL; NITRIC OXIDE SYNTHASE TYPE II; OUTCOME ASSESSMENT (HEALTH CARE); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, REGULATORY; TUMOR MICROENVIRONMENT;

EID: 84887077966     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/01.cji.0000436722.46675.4a     Document Type: Article

References (59)

1. Gooden MJ, de Bock GH, Leffers N, et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011; 105:93-103.
2. Russell SM, Angell TE, Lechner MG, et al. Immune cell infiltration patterns and survival in head and neck squamous cell carcinoma. Head Neck Oncol. 2013;5:24-33.
3. Galon J, Pagè s F, Marincola FM, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med. 2012;10:1-4.
4. Stewart TJ, Smyth MJ. Improving cancer immunotherapy by targeting tumor-induced immune suppression. Cancer Metastasis Rev. 2011;30:125-140.
5. Gajewski TF, Louahed J, Brichard VG. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J. 2010;16: 399-403.
6. May KF Jr, Gulley JL, Drake CG, et al. Prostate cancer immunotherapy. Clin Cancer Res. 2011;17:5233-5238.
7. Lechner MG, Russell SM, Bass RS, et al. Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors. Immunotherapy. 2011;3:1317-1340.
8. Callahan MK, Wolchok JD, Allison JP. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol. 2010;37:473-484.
9. Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol. 2010;37:499-507.
10. Shablak A, Sikand K, Shanks JH, et al. High-dose interleukin-2 can produce a high rate of response and durable remissions in appropriately selected patients with metastatic renal cancer. J Immunother. 2011;34:107-112.
11. McDermott DF. Improving the therapeutic index of IL-2. Clin Adv Hematol Oncol. 2010;8:862-864.
12. Kirkwood JM, Tarhini AA. Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy. J Clin Oncol. 2009; 27:2583-2585.
13. Mlecnik B, Bindea G, Pagè s F, et al. Tumor immunosurveillance in human cancers. Cancer Metastasis Rev. 2011; 30:5-12.
14. Stewart TJ, Abrams SI. How tumours escape mass destruction. Oncogene. 2008;27:5894-5903.
15. Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol. 2003;195:346-355. (Pubitemid 36529863)
16. Du C, Wang Y. The immunoregulatory mechanisms of carcinoma for its survival and development. J Exp Clin Cancer Res. 2011;30:12-21.
17. Sadun RE, Sachsman SM, Chen X, et al. Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy. Clin Cancer Res. 2007;13:4016-4025. (Pubitemid 47037610)
18. Schaer DA, Lesokhin AM, Wolchok JD. Hiding the road signs that lead to tumor immunity. J Exp Med. 2011;208: 1937-1940.
19. Fridman WH, Galon J, Pagès F, et al. Prognostic and predictive impact of intra-and peritumoral immune infiltrates. Cancer Res. 2011;71:5601-5605.
20. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960-1964. (Pubitemid 44498003)
21. Lechner MG, Megiel C, Russell SM, et al. Functional characterization of human Cd33+ and Cd11b+ myeloidderived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. J Transl Med. 2011;9:90-109.
22. Murphy KA, Lechner MG, Popescu FE, et al. An in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomas. Clin Cancer Res. 2012;18:4657-4668.
23. Wiesner SM, Decker SA, Larson JD, et al. De novo induction of genetically engineered brain tumors in mice using plasmid DNA. Cancer Res. 2009;69:431-439.
24. Russell SM, Lechner MG, Gong L, et al. USC-HN2, a new model cell line for recurrent oral cavity squamous cell carcinoma with immunosuppressive characteristics. Oral Oncol. 2011;47:810-817.
25. Li J, Hu P, Khawli LA, et al. LEC/chTNT-3 fusion protein for the immunotherapy of experimental solid tumors. J Immunother. 2003;26:320-331. (Pubitemid 36858716)
26. Li J, Hu P, Khawli LA, et al. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25+ T-cell depletion. Cancer Res. 2003;63:8384-8392. (Pubitemid 37549493)
27. Katz JB, Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev. 2008;222:206-221. (Pubitemid 351430372)
28. Condamine T, Gabrilovich DI. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 2011;32:19-25.
29. Mocellin S, Wang E, Marincola FM. Cytokines and immune response in the tumor microenvironment. J Immunother. 2001;24:392-407. (Pubitemid 33029909)
30. Ostrand-Rosenberg S. Animal models of tumor immunity, immunotherapy and cancer vaccines. Curr Opin Immunol. 2004;16:143-150. (Pubitemid 38328715)
31. von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, et al. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood. 2002;99:3319-3325. (Pubitemid 34525313)
32. Lynch DH. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer. Immunol Rev. 2008;222:277-286. (Pubitemid 351430383)
33. Jensen SM, Maston LD, Gough MJ, et al. Signaling through OX40 enhances antitumor immunity. Semin Oncol. 2010;37:524-532.
34. Placke T, Kopp HG, Salih HR. Glucocorticoid-induced TNFR-related (GITR) protein and its ligand in antitumor immunity: functional role and therapeutic modulation. Clin Dev Immunol. 2010;2010:239083.
35. Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol. 2010;185:2273-2284.
36. Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56:641-648. (Pubitemid 46348738)
37. Zhao J, Cao Y, Lei Z, et al. Selective depletion of CD4+ CD25 +Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Res. 2010;70:4850-4858.
38. Lechner MG, Epstein AL. A new mechanism for blocking myeloid-derived suppressor cells by CpG. Clin Cancer Res. 2011;17:1645-1648.
39. Vincent J, Mignot G, Chalmin F, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010;70:3052-3061.
40. Salazar AM, Levy HB, Ondra S, et al. Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study. Neurosurgery. 1996;38:1096-1103.
41. Lechner MG. Human Myeloid-derived Suppressor Cells in Cancer: Induction, Functional Characterization, and Therapy [Thesis Dissertation]. Los Angeles, CA: University of Southern California, Department of Pathology of the Keck School of Medicine; 2011.
42. Gajewski TF, Fuertes M, Spaapen R, et al. Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol. 2011;23: 286-292.
43. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331:1565-1570.
44. Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410:1107-1111. (Pubitemid 32391043)
45. Zeiser R, Schnitzler M, Andrlova H, et al. Immunotherapy for malignant melanoma. Curr Stem Cell Res Ther. 2012;7: 217-228.
46. Kjaergaard J, Tanaka J, Kim JA, et al. Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res. 2000;60: 5514-5521.
47. Chen L, McGowan P, Ashe S, et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med. 1994;179:523-532.
48. Gajewski TF, Meng Y, Harlin H. Chemokines expressed in melanoma metastases associated with T cell infiltration. J Clin Oncol-2007 ASCO Annu Meeting Proc Part I. 2007; 25(18S):8501.
49. Gajewski TF, Zha Y, Thurner B, et al. Association of gene expression profile in melanoma and survival to a dendritic cellbased vaccine. J Clin Oncol. 2009;27(15S):9002.
50. Louahed J, Gruselle O, Gaulis S, et al. Expression of defined genes identified by pre-treatment tumor profiling: association with clinical responses to the GSK MAGE-A3 immunotherapeutic in metastatic melanoma patients. J Clin Oncol. 2008; 26(suppl):9045.
51. Lima L, Dinis-Ribeiro M, Longatto-Filho A, et al. Predictive biomarkers of Bacillus Calmette-Guérin immunotherapy response in bladder cancer: where are we now? Adv Urol. 2012;2012:232609.
52. Watanabe E, Matsuyama H, Matsuda K, et al. Urinary interleukin-2 may predict clinical outcome of intravesical Bacillus Calmette-Guérin immunotherapy for carcinoma in situ of the bladder. Cancer Immunol Immunother. 2003; 52:481-486. (Pubitemid 36963209)
53. Hoos A, Ibrahim R, Korman A, et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol. 2010;37:533-546.
54. LeBerthon B, Khawli LA, Alauddin M, et al. Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleukin 2 immunoconjugate. Cancer Res. 1991;51: 2694-2698.
55. Schwaab T, Schwarzer A, Wolf B, et al. Clinical and immunologic effects of intranodal autologous tumor lysatedendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients. Clin Cancer Res. 2009;15:4986-4992.
56. Okada H, Kalinski P, Ueda R, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol. 2011;29:330-336.
57. Yokouchi H, Yamazaki K, Chamoto K, et al. Anti-OX40 monoclonal antibody therapy in combination with radiotherapy results in therapeutic antitumor immunity to murine lung cancer. Cancer Sci. 2008;99:361-367. (Pubitemid 351228493)
58. Gough MJ, Crittenden MR, Sarff M, et al. Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice. J Immunother. 2010;33:798-809.
59. Hirschhorn-Cymerman D, Rizzuto GA, Merghoub T, et al. OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J Exp Med. 2009;206:1103-1116.